Effectiveness of Continuous Subcutaneous Insulin Infusion Pump Therapy During Five Years of Treatment on Metabolic Control in Children and Adolescents with Type 1 Diabetes Mellitus
Küçük Resim Yok
Tarih
2018
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Yayincilik
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: To compare continuous subcutaneous insulin infusion (CSII) therapy with multiple daily insulin (MDI) therapy on metabolic control in children and adolescents with type I diabetes mellitus (T1DM) over the long term. Methods: Fifty-two T1DM patients treated with CSII and monitored for at least one year prior to and at least five years following CSII were included. Thirty-eight age and sex-matched MDI controls with a 5-year follow up were recruited. Results: Mean age of the subjects, duration of diabetes and CSII therapy were 17.0 +/- 4.8 years, 10.7 +/- 2.8 years and 7.7 +/- 1.5 years respectively. Mean hemoglobin A1c (HbA I c) in the year prior to CSII, during the first year of treatment and after 5 years of CSII were 7.3 +/- 1 % (56 mmol/mol), 7.0 +/- 0.7% (53 mmol/mol) and 7.8 +/- 1.3 % (62 mmol/mol) respectively. Initial and 5-year mean HbA1C levels of controls were 7.9 +/- 1.08 % and 8.6 +/- 1.8 %. Mean HbA1c values were significantly lower in those receiving CSII therapy throughout follow-up. Basal and total insulin doses were significantly lower in the CSII group at all times. HbA1c was compared between subjects by age (0-5, 6-11 and 12-18 years) with no significant difference between them. Conclusion: Although CSII mean HbA1c values exceeded accepted good metabolic control limits after 5 years, CSII produces better HbA1c control at all times and in all age groups compared to MDI.
Açıklama
Anahtar Kelimeler
Type 1 diabetes mellitus, continuous subcutaneous insulin infusion pump therapy, multiple daily insulin therapy, HbA1c
Kaynak
Journal of Clinical Research in Pediatric Endocrinology
WoS Q Değeri
Q3
Scopus Q Değeri
Cilt
10
Sayı
2
